申请人:SMITH KLINE & FRENCH LABORATORIES
LIMITED
公开号:EP0181163A2
公开(公告)日:1986-05-14
Compounds of the formula (I):
or pharmaceutically acceptable salts thereof, wherein :
R1 and R2 are independently C1-4alkyl; or R1 and R2 together with the nitrogen atom to which they are joined represent a pyrrolidino, piperidino or hexahydroazepino ring; Y is straight-chain or branched-chain C1-4alkyl; n is 2 to 5; m is 0 or 1; when m is 1, Z is inter alia an optionally substituted pyridine, pyrimidine, oxazole, thiazole, imidazole, benzoxazole benzthiazole or N-alkylbenzimidazole ring; when m is 0, Z is an optionally substituted imidazole, pyrazole or benzimidazole ring.
The compounds are histamine H2-receptors antagonists and relatively lipophilic and can penetrate the blood-brain barrier and are useful in treating diseases mediated via histamine H2-receptors. Processes for their preparation, pharmaceutical compositions and methods of use are described.
式 (I) 的化合物:
或其药学上可接受的盐,其中:
R1 和 R2 独立地为 C1-4 烷基;或 R1 和 R2 连同与之相连的氮原子代表吡咯烷、哌啶或六氢氮杂环; Y 为直链或支链 C1-4 烷基;n 为 2 至 5;m 为 0 或 1;当 m 为 1 时,Z 特别是任选取代的吡啶、嘧啶、噁唑、噻唑、咪唑、苯并噁唑苯并噻唑或 N-烷基苯并咪唑环;当 m 为 0 时,Z 是任选取代的咪唑、吡唑或苯并咪唑环。
这些化合物是组胺 H2 受体拮抗剂,具有相对亲脂性,可穿透血脑屏障,有助于治疗通过组胺 H2 受体介导的疾病。本文介绍了这些化合物的制备工艺、药物组合物和使用方法。